Free Trial

D. E. Shaw & Co. Inc. Decreases Stake in Quanterix Co. (NASDAQ:QTRX)

Quanterix logo with Medical background

D. E. Shaw & Co. Inc. trimmed its holdings in Quanterix Co. (NASDAQ:QTRX - Free Report) by 56.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,192 shares of the company's stock after selling 106,200 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.21% of Quanterix worth $874,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Resona Asset Management Co. Ltd. purchased a new stake in shares of Quanterix in the fourth quarter valued at $55,000. Tower Research Capital LLC TRC lifted its stake in Quanterix by 219.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock worth $61,000 after purchasing an additional 3,915 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Quanterix during the fourth quarter worth approximately $66,000. Cetera Investment Advisers acquired a new stake in shares of Quanterix during the fourth quarter worth approximately $108,000. Finally, Canada Pension Plan Investment Board increased its holdings in shares of Quanterix by 64.5% in the fourth quarter. Canada Pension Plan Investment Board now owns 10,200 shares of the company's stock valued at $108,000 after purchasing an additional 4,000 shares in the last quarter. 86.48% of the stock is currently owned by institutional investors and hedge funds.

Quanterix Stock Up 2.1%

NASDAQ:QTRX traded up $0.11 during trading hours on Wednesday, hitting $5.20. 545,684 shares of the stock traded hands, compared to its average volume of 573,109. Quanterix Co. has a 1 year low of $4.05 and a 1 year high of $19.18. The company has a market cap of $201.76 million, a price-to-earnings ratio of -4.91 and a beta of 1.12. The stock has a 50 day moving average price of $5.55 and a 200 day moving average price of $8.34.

Quanterix (NASDAQ:QTRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.16. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The company had revenue of $30.33 million for the quarter, compared to analysts' expectations of $28.27 million. Equities analysts forecast that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Leerink Partners reiterated a "market perform" rating and issued a $8.00 price target (down from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. Scotiabank restated an "outperform" rating on shares of Quanterix in a research report on Tuesday, March 25th. Wall Street Zen lowered shares of Quanterix from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Leerink Partnrs lowered shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Finally, Canaccord Genuity Group lowered their price target on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $15.60.

Check Out Our Latest Analysis on Quanterix

Quanterix Profile

(Free Report)

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

Further Reading

Institutional Ownership by Quarter for Quanterix (NASDAQ:QTRX)

Should You Invest $1,000 in Quanterix Right Now?

Before you consider Quanterix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quanterix wasn't on the list.

While Quanterix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines